Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Synthesis of optically active SARS-CoV-2 Mpro inhibitor drug nirmatrelvir (Paxlovid): an approved treatment of COVID-19

Organic & Biomolecular Chemistry(2023)10.1039/d3ob00653kSource: DataRank Database

Synthesis of optically active SARS-CoV-2 Mpro inhibitor drug nirmatrelvir (Paxlovid): an approved treatment of COVID-19 is a research paper published in Organic & Biomolecular Chemistry (2023). On theSindex it has a DataRank of 0. It has been cited 8 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access8 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 1.13)OA: greenTopics (36)IDs (PubMed, PMC, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Monika Yadav ORCID,Arun K. Ghosh ORCID

Live enrichment

PubMed:37293830 PMC:PMC10526638 OpenAlex:https://openalex.org/W4379967405

Foundation for the National Institutes of Health

Grant: AI158649

Foundation for the National Institutes of Health

Grant: P30CA023168

NIAID NIH HHS

Grant: R01 AI158649

NIAID NIH HHS

Grant: P01 AI060915

FWCI

1.13

Citation Percentile

0.8%

Citation Trend

2024

2025

2026

greenLicense: http://rsc.li/journals-terms-of-use

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10526638/pdf/nihms-1908842.pdf

publisherhttp://pubs.rsc.org/en/content/articlepdf/2023/OB/D3OB00653K

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10526638

journalhttps://doi.org/10.1039/d3ob00653k

Fields of Study

Computational Drug Discovery MethodsSynthesis and biological activityClick Chemistry and ApplicationsHumansSARS-CoV-2COVID-19ProlineAntiviral AgentsDrug CombinationsLactamsLeucineNitrilesRitonavir

MeSH Terms

COVID-19SARS-CoV-2Antiviral AgentsDrug CombinationsHumansLactamsLeucineNitrilesProlineRitonavir

Keywords

Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DrugEpimer2019-20 coronavirus outbreakOptically activePharmacologyMedicineVirologyChemistryStereochemistryInternal medicineInfectious disease (medical specialty)